|
Market Data
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. is a global provider of containment and delivery systems for injectable drugs and healthcare products, serving the pharmaceutical industry across multiple continents. The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. Its Proprietary Products segment focuses on developing and supplying critical components like stoppers, seals, syringes, and advanced drug delivery systems, including innovative solutions like Crystal Zenith. Simultaneously, the Contract-Manufactured Products segment designs and assembles devices for surgical, diagnostic, and drug delivery applications. West Pharmaceutical Services, Inc. distributes its products through a combination of direct sales, distribution networks, and contract agents, solidifying its position as a key partner for pharmaceutical and medical device companies.
WST is currently trading at $273.88, giving West Pharmaceutical Services, Inc. a market cap of 19.34B and a P/E ratio of 39.2. Today's range spans $269.98–$275.43, with shares opening at $272.31 and moving up $0.22 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 74/100.
Over the past year WST has traded between $193.05 and $322.34 - the current price is +41.9% off the 52-week low and -15.0% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $317.46 (range $275.00–$375.00), implying upside of +15.9%.
The Healthcare sector has plenty of names, but WST is one of the few right now where technical and sentiment data are both bullish. Score: 86/100 (BUY). Sentiment: bullish (74/100). Price: $273.88 (in the middle of its 52-week range). The current P/E ratio stands at 39.2. With 19.34B in market cap, this is the scale where fundamental thesis and technical setup reinforce rather than compete with each other. Annual range: $193.05–$322.34.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.68 | - | - |
| Q4'25 | $1.67 | $2.04 | +22.1% |
| Q3'25 | $1.71 | $1.96 | +14.6% |
| Q2'25 | $1.54 | $1.84 | +19.7% |
| Q1'25 | $1.26 | $1.45 | +15.3% |
| Q4'24 | $1.73 | $1.82 | +5.3% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $779M | - | - |
| Q4'25 | $773M | $805M | +4.1% |
| Q3'25 | - | $805M | - |
| Q2'25 | - | $767M | - |
| Q1'25 | - | $698M | - |
| Q4'24 | - | $749M | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).